CL2017003152A1 - Composiciones de hidroxipropil beta-ciclodextrina y métodos - Google Patents

Composiciones de hidroxipropil beta-ciclodextrina y métodos

Info

Publication number
CL2017003152A1
CL2017003152A1 CL2017003152A CL2017003152A CL2017003152A1 CL 2017003152 A1 CL2017003152 A1 CL 2017003152A1 CL 2017003152 A CL2017003152 A CL 2017003152A CL 2017003152 A CL2017003152 A CL 2017003152A CL 2017003152 A1 CL2017003152 A1 CL 2017003152A1
Authority
CL
Chile
Prior art keywords
methods
mixtures
hydroxypropyl beta
cyclodextrin compositions
intratecal
Prior art date
Application number
CL2017003152A
Other languages
English (en)
Inventor
Bernardus Nicolaas Machielse
Allan Darling
Original Assignee
Vtesse Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtesse Inc filed Critical Vtesse Inc
Publication of CL2017003152A1 publication Critical patent/CL2017003152A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA MEZCLAS DE MOLÉCULAS DE BETA–CICLODEXTRINAS SUSTITUIDAS EN UNA O MÁS POSICIONES HIDROXILO CON GRUPOS HIDROXIPROPILO, DONDE LA MEZCLA, EN FORMA OPCIONAL, INCLUYE MOLÉCULAS DE BETA–CICLODEXTRINAS NO SUSTITUIDAS, PARA EL USO COMO UN INGREDIENTE FARMACÉUTICAMENTE ACTIVO; MÉTODOS DE ELABORACIÓN DE DICHAS MEZCLAS; MÉTODOS DE CALIFICACIÓN DE DICHAS MEZCLAS PARA EL USO EN UNA COMPOSICIÓN FARMACÉUTICA ADECUADA PARA LA ADMINISTRACIÓN INTRATECAL O INTRACEREBROVENTRICULAR; COMPOSICIONES FARMACÉUTICAS ADECUADAS PARA LA ADMINISTRACIÓN INTRATECAL O INTRACEREBROVENTRICULAR QUE COMPRENDEN DICHAS MEZCLAS; Y MÉTODOS DE USO DE LAS COMPOSICIONES FARMACÉUTICAS PARA EL TRATAMIENTO DE LA ENFERMEDAD DE NIEMANN–PICK TIPO C.</p>
CL2017003152A 2015-06-10 2017-12-07 Composiciones de hidroxipropil beta-ciclodextrina y métodos CL2017003152A1 (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562173889P 2015-06-10 2015-06-10
US201562175075P 2015-06-12 2015-06-12
US201562189114P 2015-07-06 2015-07-06
US201562245974P 2015-10-23 2015-10-23
US201562249876P 2015-11-02 2015-11-02
US201562263599P 2015-12-04 2015-12-04
US201662276728P 2016-01-08 2016-01-08
US201662308736P 2016-03-15 2016-03-15
US201662314765P 2016-03-29 2016-03-29
US201662331385P 2016-05-03 2016-05-03
US201662345721P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
CL2017003152A1 true CL2017003152A1 (es) 2018-04-27

Family

ID=57504353

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003152A CL2017003152A1 (es) 2015-06-10 2017-12-07 Composiciones de hidroxipropil beta-ciclodextrina y métodos

Country Status (16)

Country Link
US (23) US20160361345A1 (es)
EP (1) EP3307278A4 (es)
JP (1) JP2018517046A (es)
KR (1) KR20180035787A (es)
CN (1) CN107847517A (es)
AU (1) AU2016276774A1 (es)
BR (1) BR112017026287A2 (es)
CA (1) CA2988529A1 (es)
CL (1) CL2017003152A1 (es)
EA (1) EA033892B1 (es)
HK (1) HK1247856A1 (es)
IL (1) IL255991A (es)
MX (1) MX2017015879A (es)
TW (1) TW201716070A (es)
WO (1) WO2016201137A1 (es)
ZA (1) ZA201708414B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017026287A2 (pt) 2015-06-10 2018-09-18 Vtesse Inc composições de hidroxipropil beta-ciclodextrina e métodos
LU100797B1 (en) 2018-05-15 2019-11-15 Univ Luxembourg 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition
FR3083234B1 (fr) 2018-06-29 2020-11-27 Roquette Freres Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
JP2021529243A (ja) * 2018-06-29 2021-10-28 ロケット フレールＲｏｑｕｅｔｔｅ Ｆｒｅｒｅｓ 新規なヒドロキシプロピル−β−シクロデキストリン及びそれを生成するための方法
CN112996562A (zh) 2018-10-29 2021-06-18 赛克洛治疗股份有限公司 治疗阿尔茨海默病的方法
CN113490691A (zh) 2019-01-03 2021-10-08 劣势者药物有限公司 环糊精二聚体、其组合物及其用途
CA3136360A1 (en) * 2019-04-12 2020-10-15 Loma Linda University Methods for treatment of niemann-pick disease type c
US11446325B2 (en) 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
CN113457468B (zh) * 2021-06-24 2022-10-28 北京工业大学 一种单宁酸-羟丙基β环糊精复合纳滤膜及其制备方法
US11958917B2 (en) 2022-02-18 2024-04-16 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
WO2023242737A1 (en) * 2022-06-13 2023-12-21 Beren Therapeutics P.B.C. Systems and methods for manufacturing hydroxypropyl-beta-cyclodextrin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5262404A (en) 1990-02-15 1993-11-16 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
ZA927923B (en) * 1991-10-16 1993-04-26 Schering Corp Lipophilic oligosaccharide antibiotic salt compositions.
EP0803243B1 (en) * 1996-04-24 2003-03-19 Pfizer Inc. Cyclodextrins and phenolic compounds in dental products
FR2767834B1 (fr) 1997-08-29 1999-12-03 Inst Francais Du Petrole Mono et di-derives de cyclodextrines, leurs synthese et purification et leur utilisation en support
AU2001259725A1 (en) * 2000-05-15 2001-11-26 The Procter And Gamble Company Compositions comprising cyclodextrin derivatives
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005112637A1 (en) 2004-05-14 2005-12-01 Decode Chemistry, Inc. Formulations for non-parenteral use including hydrophobic cyclodextrins
EP1655034A1 (en) * 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
EP1747785A1 (en) * 2005-07-28 2007-01-31 Istituto Clinico Humanitas Cyclodextrins for blood detoxification
WO2010138802A2 (en) 2009-05-28 2010-12-02 Cornell University Compositions and their use for removing cholesterol
EP2595623B1 (en) 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
CN102040675B (zh) 2010-12-22 2012-10-03 石药集团中诺药业（石家庄）有限公司 一种羟丙基-β-环糊精的制备方法
EP4299121A2 (en) 2012-04-13 2024-01-03 L&F Research LLC Method of using cyclodextrin
AU2013296170A1 (en) 2012-08-03 2015-03-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cyclodextrin for the treatment of lysosomal storage diseases
WO2014078573A2 (en) 2012-11-16 2014-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
BR112017026287A2 (pt) 2015-06-10 2018-09-18 Vtesse Inc composições de hidroxipropil beta-ciclodextrina e métodos

Also Published As

Publication number Publication date
EP3307278A1 (en) 2018-04-18
US20220280553A1 (en) 2022-09-08
US11633423B2 (en) 2023-04-25
US11826318B2 (en) 2023-11-28
US11534456B2 (en) 2022-12-27
US20190290677A1 (en) 2019-09-26
US11406657B2 (en) 2022-08-09
US11744849B2 (en) 2023-09-05
US20230027884A1 (en) 2023-01-26
US11744848B2 (en) 2023-09-05
US20230201247A1 (en) 2023-06-29
ZA201708414B (en) 2019-11-27
US11590159B2 (en) 2023-02-28
US11938144B2 (en) 2024-03-26
US20230226101A1 (en) 2023-07-20
US10709730B2 (en) 2020-07-14
US20220288105A1 (en) 2022-09-15
US20230095371A1 (en) 2023-03-30
US11590160B2 (en) 2023-02-28
US10933083B2 (en) 2021-03-02
US11744850B2 (en) 2023-09-05
US20220280552A1 (en) 2022-09-08
TW201716070A (zh) 2017-05-16
JP2018517046A (ja) 2018-06-28
MX2017015879A (es) 2018-08-16
US11865136B2 (en) 2024-01-09
AU2016276774A1 (en) 2018-01-18
CN107847517A (zh) 2018-03-27
US11541074B2 (en) 2023-01-03
US20170042932A1 (en) 2017-02-16
EA201792487A1 (ru) 2018-06-29
US11534455B2 (en) 2022-12-27
US20230068856A1 (en) 2023-03-02
US10300086B2 (en) 2019-05-28
US11529366B2 (en) 2022-12-20
US20220280550A1 (en) 2022-09-08
US20240016829A1 (en) 2024-01-18
US20220280551A1 (en) 2022-09-08
US20190038662A1 (en) 2019-02-07
US20220273697A1 (en) 2022-09-01
EA033892B1 (ru) 2019-12-05
KR20180035787A (ko) 2018-04-06
WO2016201137A1 (en) 2016-12-15
US10258641B2 (en) 2019-04-16
US20160361345A1 (en) 2016-12-15
US11510940B2 (en) 2022-11-29
US20170296572A1 (en) 2017-10-19
US11517585B2 (en) 2022-12-06
HK1247856A1 (zh) 2018-10-05
US11918601B2 (en) 2024-03-05
US20230226102A1 (en) 2023-07-20
US9675634B2 (en) 2017-06-13
US20220280554A1 (en) 2022-09-08
US20230241094A1 (en) 2023-08-03
BR112017026287A2 (pt) 2018-09-18
IL255991A (en) 2018-01-31
US20220288106A1 (en) 2022-09-15
EP3307278A4 (en) 2018-06-13
US20210015846A1 (en) 2021-01-21
US20190224231A1 (en) 2019-07-25
CA2988529A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
CL2017003152A1 (es) Composiciones de hidroxipropil beta-ciclodextrina y métodos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
ECSP18017254A (es) Composiciones con potenciadores de permeación para suministro de fármacos
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
CY1122038T1 (el) Ετεροδιλειτουργικοι αναστολεις των ε-σελεκτινων και των υποδοχεων χημειοκινης cxcr4
CO2017001994A2 (es) Compuestos activos hacia bromodominios
PE20180260A1 (es) Metodos y kits para tratar la depresion
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CL2019000694A1 (es) Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista de péptido de tlr para tratamiento de cáncer colorrectal.
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
CO2020009670A2 (es) Composiciones que comprenden microbiota coseleccionada y métodos para su uso
CO2017002472A2 (es) Formulación de acetato de abiraterona
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
BR112018010267A2 (pt) antibióticos macrocíclicos de amplo espectro